MarketBeat
Definium Therapeutics Teases 3 Key DT-120 Data Readouts This Year, Highlights De-Risked Phase 3 Design
📈
AI Sentiment
Highly Positive
9/10
- Home
- DFTX
as of 03-23-2026 3:37pm EST
$18.24
$0.07
-0.38%
Stocks Nasdaq
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.7B | IPO Year: | N/A |
| Target Price: | $40.25 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $14.62 - $19.67 | Next Earning Date: | 05-04-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Latest Definium Therapeutics Inc. Common Shares News
DFTX Breaking Stock News: Dive into DFTX Ticker-Specific Updates for Smart Investing
Motley Fool
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names
📈
AI Sentiment
Highly Positive
8/10
Compare DFTX vs Leading Stocks
See how DFTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "DFTX Definium Therapeutics Inc. Common Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.